1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 4, 1996
ImmuLogic Pharmaceutical Corporation
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
- --------------------------------------------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-19117 13-3397957
- ------------------------ -------------------
(Commission File Number) (I.R.S. Employer
Identification No.)
610 Lincoln Street
Waltham, Massachusetts 02154
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(617) 466-6000
- --------------------------------------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
Not Applicable
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Page 1 of 6 Pages
Exhibit Index is on Page 4
2
Item 5. Other Events.
- ----------------------
On December 4, 1996, the Company announced the appointment of Dr. Joseph
Marr, M.D., Executive Vice President of Research and Development/Chief
Scientific Officer, to the additional position of acting President and Chief
Executive Officer. Dr. Marr succeeds Robert J. Gerety, following Dr. Gerety's
resignation on December 4, 1996, from the position of President and Chief
Executive Officer and Director of the Company.
In addition, Richard N. Small, Vice President and Chief Financial Officer
of the Company has accepted a position as Senior Vice President and Chief
Financial Officer at Immune Therapeutics Inc., a start-up biotechnology company
in Massachusetts. However, at the request of the Board of Directors, Rich Small
has postponed his departure to remain in his current position as Vice President
and Chief Financial Officer through a transition period.
Item 7. Financial Statements and Exhibits.
- -------------------------------------------
Exhibit
No. Description
- ------- -----------
99.1 Press Release dated December 4, 1996.
- 2 -
3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: December 13, 1996 IMMULOGIC PHARMACEUTICAL CORPORATION
/s/ Richard N. Small
----------------------------------------
By: Richard N. Small,
Title: Vice President and
Chief Financial Officer
- 3 -
4
Exhibit Index
-------------
Exhibit No. Exhibit
- ----------- -------
99.1 Press Release, dated December 4, 1996
- 4 -